TOS.TO - TSO3 Inc.

Toronto - Toronto Delayed Price. Currency in CAD
0.88
-0.04 (-4.35%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.92
Open0.89
Bid0.86 x 0
Ask0.92 x 0
Day's Range0.85 - 0.92
52 Week Range0.85 - 3.30
Volume105,709
Avg. Volume257,220
Market Cap81.744M
Beta2.72
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • ACCESSWIRE21 days ago

    Today’s Research Reports on Acerus Pharmaceuticals, TSO3, BELLUS Health and ImmunoVaccine

    NEW YORK, NY / ACCESSWIRE / April 5, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • CNW Group23 days ago

    TSO3 Appoints Dr. Douglas Dieter to its Board of Directors

    TSO3 Appoints Dr. Douglas Dieter to its Board of Directors

  • CNW Grouplast month

    TSO3 Reports Fourth Quarter and Full Year 2017 Results

    TSO3 Reports Fourth Quarter and Full Year 2017 Results

  • PR Newswirelast month

    TSO3 Reports Fourth Quarter and Full Year 2017 Results

    QUEBEC CITY and MYRTLE BEACH, SC , March 20, 2018 /PRNewswire/ - TSO 3 Inc. (TSX: TOS) ("TSO 3 " or the "Company"), an innovator in sterilization technology for medical devices in healthcare ...

  • PR Newswirelast month

    TSO3 Submits Response to US Regulators in Support of Terminal Sterilization of Duodenoscopes

    QUEBEC CITY and MYRTLE BEACH, SC, March 19, 2018 /PRNewswire/ - TSO3 Inc. (TOS.TO), ("TSO3" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, today announced that it has provided its final Additional Information (AI) response to US Regulators in support of extending the claims of the Company's STERIZONE® VP4 Sterilizer to include the terminal sterilization of duodenoscopes. In the AI response, the Company included data on modified leak test experiments, testing to confirm lack of fluid ingress occurring under the distal end cap of the devices, as well as real-world data from market research commissioned by TSO3 reflecting the actual use-life of duodenoscopes. "The Company believes that its response is consistent with 510(k) requirements demonstrating the same intended use and the same technological characteristics as the predicate device, which is the existing cleared TSO3 STERIZONE® VP4 Sterilizer" stated R.M. (Ric) Rumble, TSO3's President and CEO.

  • CNW Grouplast month

    TSO3 Submits Response to US Regulators in Support of Terminal Sterilization of Duodenoscopes

    TSO3 Submits Response to US Regulators in Support of Terminal Sterilization of Duodenoscopes

  • PR Newswirelast month

    TSO3's STERIZONE® VP4 Sterilizer Receives 510(k) Clearance for a Significant Enhancement

    All of the Company's new STERIZONE® VP4 Sterilizers, along with any upgraded units in existing inventories, can now incorporate this new feature and several other additional customer improvements intended to improve the user experience. The STERIZONE® VP4 Sterilizer is a low-temperature sterilization system that utilizes the dual-sterilants of vaporized hydrogen peroxide (H2O2) and ozone (O3) to achieve terminal sterilization of heat and moisture sensitive medical devices.

  • CNW Grouplast month

    TSO3's STERIZONE® VP4 Sterilizer Receives 510(k) Clearance for a Significant Enhancement

    TSO3's STERIZONE® VP4 Sterilizer Receives 510(k) Clearance for a Significant Enhancement

  • CNW Group2 months ago

    TSO3 Sets Fourth Quarter and Full Year 2017 Earnings Call for Wednesday, March 21, 2018 at 8:30 a.m. EDT

    TSO3 Sets Fourth Quarter and Full Year 2017 Earnings Call for Wednesday, March 21, 2018 at 8:30 a.m. EDT

  • PR Newswire2 months ago

    TSO3 Sets Fourth Quarter and Full Year 2017 Earnings Call for Wednesday, March 21, 2018 at 8:30 a.m. EDT

    QUEBEC CITY and MYRTLE BEACH, SC , March 7, 2018 /PRNewswire/ - TSO 3 Inc. (TSX: TOS) ("TSO 3 " or the "Company"), an innovator in sterilization technology for medical devices in healthcare ...

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Canopy Growth, Fennec Pharmaceuticals, Neptune Technologies & Bioressources and TSO3

    NEW YORK, NY / ACCESSWIRE / February 22, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • PR Newswire2 months ago

    TSO3 to Present at the RBC Capital Markets Healthcare Conference

    QUEBEC CITY and MYRTLE BEACH, SC, Feb. 14, 2018 /PRNewswire/ - TSO3 Inc. (TOS.TO), ("TSO3" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, today announced the Company will participate in the RBC Capital Markets Healthcare Conference in New York, New York. TSO3's management is scheduled to present on Thursday, February 22, 2018 at 1:35 PM EST. An audio webcast of the Company's presentation will be available in the investor relations section of TSO3's website at www.tso3.com.

  • CNW Group2 months ago

    TSO3 to Present at the RBC Capital Markets Healthcare Conference

    TSO3 to Present at the RBC Capital Markets Healthcare Conference

  • PR Newswire3 months ago

    IIROC Trade Resumption - TOS

    TORONTO , Jan. 25, 2018 /CNW/ - Trading resumes in: Company: TSO3 Inc. TSX Symbol: TOS (all issues) Resumption (ET): 10:45 AM IIROC can make a decision to impose a temporary suspension (halt) of trading ...

  • CNW Group3 months ago

    IIROC Trade Resumption - TOS

    IIROC Trade Resumption - TOS

  • Newsfile3 months ago

    IIROC Trade Resumption - TSO3 Inc.

    Toronto, Ontario--(Newsfile Corp. - January 25, 2018) - Trading resumes in: Company: TSO3 Inc. TSX Symbol: TOS (all issues) ...

  • PR Newswire3 months ago

    TSO3 and Global Distributor Agree on Co-Commercial Strategy for North America

    QUEBEC CITY and MYRTLE BEACH, SC, Jan. 25, 2018 /PRNewswire/ - TSO3 Inc. (TOS.TO), ("TSO3" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, announced today that, in a joint effort to increase sales to end users and optimize the customer experience, it has entered into a new agreement (the "Sales and Repurchase Agreement") with Getinge Infection Control AB, its global distribution partner. The Sales and Repurchase Agreement allows the Company to sell its STERIZONE® VP4 Sterilizers and associated products and services directly into the United States and Canada and repurchase not less than 100 STERIZONE® VP4 sterilizers for $3.3 million, with an initial order of 30 units. Getinge will continue to sell its inventory in North America and the rest of the world and the parties have agreed to a customer selection mechanism to prevent the likelihood of channel conflict.

  • CNW Group3 months ago

    TSO3 and Global Distributor Agree on Co-Commercial Strategy for North America

    TSO3 and Global Distributor Agree on Co-Commercial Strategy for North America

  • CNW Group3 months ago

    IIROC Trading Halt - TOS

    IIROC Trading Halt - TOS

  • PR Newswire3 months ago

    IIROC Trading Halt - TOS

    TORONTO , Jan. 25, 2018 /CNW/ - The following issues have been halted by IIROC: Company: TSO3 Inc. TSX Symbol: TOS (all issues) Reason: Pending News Halt Time (ET): 9:42 AM IIROC can make a decision to ...

  • Newsfile3 months ago

    IIROC Trade Halt - TSO3 Inc.

    Toronto, Ontario--(Newsfile Corp. - January 25, 2018) - The following issues have been halted by IIROC: Company:  TSO3 Inc. TSX Symbol: TOS (all issues) ...

  • CNW Group3 months ago

    TSO3 Provides an Operational Update

    TSO3 Provides an Operational Update

  • PR Newswire3 months ago

    TSO3 Provides an Operational Update

    QUEBEC CITY and MYRTLE BEACH, SC , Jan. 25, 2018 /PRNewswire/ - TSO 3 Inc. (TSX: TOS) ("TSO 3 " or the "Company"), an innovator in sterilization technology for medical devices in healthcare ...

  • PR Newswire4 months ago

    TSO3 Provides Duodenoscope Regulatory Filing Update

    QUEBEC CITY and MYRTLE BEACH, SC, Dec. 19, 2017 /PRNewswire/ - TSO3 Inc. (TOS.TO), an innovator in sterilization technology for medical devices in healthcare settings, announced today that it has had further dialogue with US Regulators in connection with their recent request for additional information (AI) regarding the Company's submission to extend claims of its STERIZONE® VP4 Sterilizer to include terminal sterilization of duodenoscopes. "We continue to work productively with US regulators in pursuit of this new indication for use of our sterilizer," stated Ric (R.M.) Rumble, President and CEO of TSO3 Inc.  "The Company has continued its testing and data compilation to further support our claims as a natural part of our internal processes.

  • CNW Group4 months ago

    TSO3 Provides Duodenoscope Regulatory Filing Update

    TSO3 Provides Duodenoscope Regulatory Filing Update